Is Teclistamab available in the country?

Teritusumab (Teclistamab-cqyv), as a new immunotherapy drug, has been approved in some countries and regions for the treatment of relapsed or refractory multiple myeloma (MM). However, currently in China, the original drug of teritusumab is already on the market, but it has not yet been included in the scope of medical insurance reimbursement. Due to the short time this drug has been on the market and its high price, its purchase channels in China are relatively limited.

The domestic selling price of Teritolumab is approximately RMB 30,000 to RMB 40,000 per box. Since the drug has just entered the market and does not generally cover hospitals and pharmacies across the country, patients need to purchase it through hospitals or some professional pharmacies. In addition, considering the high domestic prices, patients may need to pay the entire cost themselves, resulting in a certain financial burden.

On the other hand, in overseas markets, the original drug of teritusumab has also been launched and can be purchased through multiple channels. The price of European original drugs is generally about more than RMB 10,000 per box of 30mg/3ml, while the price of each box of 153mg/1.7ml (90mg/ml) may reach more than RMB 50,000. As cross-border drug purchasing has gradually become an option, some patients choose to obtain drugs through overseas purchasing, but they will also face additional costs in terms of tariffs, transportation, etc.

With the advancement of teritusumab's domestic launch, it is expected that its purchase channels will gradually increase, and it may be included in the scope of medical insurance in the future, reducing the financial burden of patients. However, at this stage, due to the high drug prices and limited medical insurance reimbursement coverage, patients still need to carefully consider their financial situation when purchasing and discuss with their doctors whether to choose such treatment.

In general, teritusumab is not yet popular in the domestic market, has a high price, and is not yet included in medical insurance, which makes some patients face certain difficulties in obtaining the drug. However, with further promotion of drugs and updates to medical insurance policies, patients' medication choices are expected to improve.

Keyword tag:

Teclistamab, Teclistamab, purchase route, price, domestic listing, medical insurance, multiple myeloma, cross-border drug purchase, drug price

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/tecvayli